Your browser doesn't support javascript.
loading
Regulation of cellular proliferation in acute lymphoblastic leukemia by Casein Kinase II (CK2) and Ikaros.
Gowda, Chandrika; Song, Chunhua; Kapadia, Malika; Payne, Jonathon L; Hu, Tommy; Ding, Yali; Dovat, Sinisa.
Afiliação
  • Gowda C; Department of Pediatrics, Pennsylvania State University College of Medicine, Hershey, PA, 17033, USA.
  • Song C; Department of Pediatrics, Pennsylvania State University College of Medicine, Hershey, PA, 17033, USA.
  • Kapadia M; Department of Pediatrics, Pennsylvania State University College of Medicine, Hershey, PA, 17033, USA.
  • Payne JL; Department of Pediatrics, Pennsylvania State University College of Medicine, Hershey, PA, 17033, USA; Loma Linda University, Loma Linda, CA, USA.
  • Hu T; Department of Pediatrics, Pennsylvania State University College of Medicine, Hershey, PA, 17033, USA.
  • Ding Y; Department of Pediatrics, Pennsylvania State University College of Medicine, Hershey, PA, 17033, USA.
  • Dovat S; Department of Pediatrics, Pennsylvania State University College of Medicine, Hershey, PA, 17033, USA. Electronic address: sdovat@hmc.psu.edu.
Adv Biol Regul ; 63: 71-80, 2017 Jan.
Article em En | MEDLINE | ID: mdl-27666503
ABSTRACT
The IKZF1 gene encodes the Ikaros protein, a zinc finger transcriptional factor that acts as a master regulator of hematopoiesis and a tumor suppressor in leukemia. Impaired activity of Ikaros is associated with the development of high-risk acute lymphoblastic leukemia (ALL) with a poor prognosis. The molecular mechanisms that regulate Ikaros' function as a tumor suppressor and regulator of cellular proliferation are not well understood. We demonstrated that Ikaros is a substrate for Casein Kinase II (CK2), an oncogenic kinase that is overexpressed in ALL. Phosphorylation of Ikaros by CK2 impairs Ikaros' DNA-binding ability, as well as Ikaros' ability to regulate gene expression and function as a tumor suppressor in leukemia. Targeting CK2 with specific inhibitors restores Ikaros' function as a transcriptional regulator and tumor suppressor resulting in a therapeutic, anti-leukemia effect in a preclinical model of ALL. Here, we review the genes and pathways that are regulated by Ikaros and the molecular mechanisms through which Ikaros and CK2 regulate cellular proliferation in leukemia.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Cromatina / Linfócitos T / Caseína Quinase II / Fator de Transcrição Ikaros / Leucemia-Linfoma Linfoblástico de Células Precursoras Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Adv Biol Regul Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Cromatina / Linfócitos T / Caseína Quinase II / Fator de Transcrição Ikaros / Leucemia-Linfoma Linfoblástico de Células Precursoras Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Adv Biol Regul Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos